Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 17/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 17/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | PRKX | P51817 | 1/20 | 0.40 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29569347 | 0.87 | TACR1 (0.40) | HCRTR1HCRTR2IDO1 | |
| SCHEMBL21723019 | 0.81 | IDO1 (0.44) | HCRTR1IDO1S1PR1PRKXIKBKE | |
| SCHEMBL19411886 | 0.76 | IDO1 (0.48) | IDO1S1PR1PRKXIKBKES1PR5 | |
| SCHEMBL27160732 | 0.76 | IDO1 (0.46) | IDO1S1PR1PRKXIKBKES1PR5 | |
| SCHEMBL26763462 | 0.76 | MGLL (0.63) | — | |
| SCHEMBL29882564 | 0.76 | MGLL (0.63) | — | |
| SCHEMBL23149358 | 0.76 | MGLL (0.63) | — | |
| SCHEMBL29882942 | 0.76 | MGLL (0.63) | — | |
| SCHEMBL31308833 | 0.75 | IDO1 (0.49) | IDO1S1PR1PRKXIKBKES1PR5 | |
| Trifluoroacetic Acid SCHEMBL23149351 | 0.74 | IDO1 (0.41) | IDO1S1PR1PRKXIKBKES1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4028401-B1 | 4,4A,5,7,8,8A-HEXAPYRIDO[4,3-B][1,4]OXAZIN-3-ONE COMPOUNDS AS MAGL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-11-22 | — | — | EP | disclosed |
| US-20210094971-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094971-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP4B1, CYP4X1 | HCRTR1 310/4885HCRTR2 732/4885IDO1 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.